Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Johnson & Johnson vs. Merck

TheMotleyFool

0 0

Better Buy: Johnson & Johnson vs. MerckPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Johnson & Johnson (NYSE: JNJ) and Merck & Co. (NYSE: MRK) are two heavyweights in the pharmaceutical sector. Both companies generate billions in sales and profits and have developed many successful drugs over the years.

However, both underperformed in 2019. Merck's 19% return last year was well above the 13% that Johnson & Johnson produced for its investors, but shares of both companies still fell well shy of the 30% return enjoyed by the S&P 500.

Deciding which stock is the better buy today is no easy task. Both offer investors some great opportunities in healthcare, and there's not a whole lot separating the two. Let's take a closer look at the two stocks to see which one has the edge today.

Source Fool.com

Like: 0

MRK

Teilen